Prognostic significance of histopathology of primary conjunctival melanoma in caucasians

Current Eye Research

Volumn 32, Issue 11, 2007, Pages 939-952

  Tuomaala, Seppo ^a   Toivonen, Päivi ^a   Al Jamal, Ranaa ^a   Kivelä, Tero ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Conjunctiva; Histopathology; Melanoma

Indexed keywords

MITOMYCIN C;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CAUCASIAN; CONJUNCTIVA TUMOR; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CELL NUCLEOLUS; CONJUNCTIVAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FINLAND; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MALE; MELANOMA; MIDDLE AGED; MITOTIC INDEX; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE;

EID: 36248941589     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680701648019     Document Type: Article

References (57)

1. Tuomaala S, Eskelin S, Tarkkanen A, Kivelä T. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci. 2002;43:3399-3408.
2. Inskip PD, Devesa SS, Fraumeni JF. Trends in the incidence of ocular melanoma in the United States, 1974-1998. Cancer Causes Control. 2003;14:251-257.
3. Yu GP, Hu DN, McCormick S, Finger PT. Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol. 2003;135:800-806.
4. Tuomaala S, Kivelä T. Metastatic pattern and survival in disseminated conjunctival melanoma: implications for sentinel lymph node biopsy. Ophthalmology. 2004;111:816-821.
5. de Wolff-Rouendaal D. Conjunctival melanoma in the Netherlands: a clinico-pathological and follow-up study. M.D. Thesis. Leiden: University of Leiden, The Netherlands, 1990.
6. Esmaeli B, Wang, X, Youssef, A, Gershenwald, JE. Patterns of regional and distant metastasis in patients with conjunctival melanoma. Experience at a cancer center over four decades. Ophthalmology. 2001;108:2101-2105.
7. Folberg R, McLean IW, Zimmerman LE. Conjunctival melanosis and melanoma. Ophthalmology. 1984;91:673-678.
8. Shields CL. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Trans Am Ophthalmol Soc. 2000;98:471-492.
9. Eskelin S, Summanen P, Pyrhönen S, Tarkkanen A, Kivelä T. Screening for metastatic uveal melanoma revisited. Cancer. 1999;85:1151-1159.
10. Missotten GS, Keijser S, De Keizer RJ, de Wolff-Rouendaal D. Conjunctival melanoma in the Netherlands: a nationwide study. Invest Ophthalmol Vis Sci. 2005;46:75-82.
11. Silvers DN, Jakobiec FA, Freeman TR, Lefkowitch JH, Elie RC. Melanoma of the conjunctiva: a clinicopathological study. In: Jakobiec FA, ed. Ocular and Adnexal Tumors. Birmingham: Aesculapius, 1978; 582-599.
12. Lommatzsch PK, Lommatzsch RE, Kirsch I, Fuhrmann P. Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva. Br J Ophthalmol. 1990;74:615-619.
13. Paridaens ADA, Minassian DC, McCartney ACE, Hungerford JL. Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol. 1994;78:252-259.
14. Folberg R, McLean IW, Zimmerman LE. Malignant melanoma of the conjunctiva. Hum Pathol. 1985;16:136-143.
15. De Potter P, Shields CL, Shields JA, Menduke H. Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases. Br J Ophthalmol. 1993;77:624-630.
16. Anastassiou G, Esser M, Bader E, Steuhl KP, Bornfeld N. Expression of cell adhesion molecules and tumour infiltrating leucocytes in conjunctival melanoma. Melanoma Res. 2004;14:381-385.
17. Anastassiou G, Heiligenhaus A, Bechrakis N, Bader E, Bornfeld N, Steuhl KP. Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol. 2002;86:163-167.
18. Bobic-Radovanovic A, Latkovic Z, Marinkovic J, Radovanovic Z. Predictors of survival in malignant melanoma of the conjunctiva: a clinico-pathological and follow-up study. Eur J Ophthalmol. 1998;8:4-7.
19. Seregard S, Oskarsson M, Spångberg B. PC-10 as a predictor of prognosis after antigen retrieval in posterior uveal melanoma. Invest Ophthalmol Vis Sci. 1996;37:1451-1458.
20. Seregard S, Kock E. Conjunctival malignant melanoma in Sweden 1969-91. Acta Ophthalmol (Copenh). 1992;70:289-296.
21. Jeffrey IJ, Lucas DR, McEwan C, Lee WR. Malignant melanoma of the conjunctiva. Histopathology. 1986;10:363-378.
22. Werschnik C, Lommatzsch PK. Long-term follow-up of patients with conjunctival melanoma. Am J Clin Oncol. 2002;25:248-255.
23. Shields CL, Shields JA, Gunduz K, Cater J, Mercado GV, Gross N, Lally B. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol. 2000;118:1497-1507.
24. Seregard S, Spångberg B, Juul C, Oskarsson M. Prognostic accuracy of the mean of the largest nucleoli, vascular patterns, and PC-10 in posterior uveal melanoma. Ophthalmology. 1998;105:485-91.
25. Moshari A, McLean IW. Uveal melanoma: mean of the longest nucleoli measured on silver-stained sections. Invest Ophthalmol Vis Sci. 2001;42:1160-1163.
26. Al Jamal RT, Mäkitie T, Kivelä T. Nucleolar diameter and microvascular factors as independent predictors of mortality from malignant melanoma of the choroid and ciliary body. Invest Ophthalmol Vis Sci. 2003;44:2381-2389.
27. McLean IW, Keefe KS, Burnier MN. Uveal melanoma: comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. Ophthalmology. 1997;104:777-780.
28. Sørensen FB, Gamel JW, Jensen OA, Ladekarl M, McCurdy J. Prognostic value of nucleolar size and size pleomorphism in choroidal melanomas. APMIS. 1993;101:358-368.
29. Gamel JW, McCurdy JB, McLean IW. A comparison of prognostic covariates for uveal melanoma. Invest Ophthalmol Vis Sci. 1992;33:1919-1922.
30. Huntington A, Haugan P, Gamel J, McLean I. A simple cytologic method for predicting the malignant potential of intraocular melanoma. Pathol Res Practice. 1989;185:631-634.
31. Folberg R, Rummelt V, Parys-van Ginderdeuren R, Hwang T, Woolson RF, Pe'er J, Gruman LM. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389-1398.
32. Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst. 1999;91:359-367.
33. Foss AJE, Alexander RA, Hungerford JL, Harris AL, Cree IA, Lightman S. Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol. 1997;81:240-246.
34. Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci. 1999;40:2471-480.
35. Foss AJE, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S. Microvessel count predicts survival in uveal melanoma. Cancer Res. 1996;56:2900-2903.
36. + cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:1414-1421.
37. Toivonen P, Mäkitie T, Kujala E, Kivelä T. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. Invest Ophthalmol Vis Sci. 2004;45:1-6.
38. Tuomaala S, Aine E, Saari KM, Kivelä T. Corneally displaced malignant conjunctival melanomas. Ophthalmology. 2002;109:914-919.
39. Folberg R, Pe'er J, Gruman LM, Woolson RF, Jeng G, Montague PR, Moninger TO, Yi H, Moore KC. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol. 1992;23:1298-1305.
40. Ramani P, Bradley NJ, Fletcher CDM. QBEND/10, a new monoclonal antibody to endothelium: assessment of its diagnostic utility in paraffin sections. Histopathology. 1990;17:237-242.
41. Parmar MKB, Machin D. Survival Analysis. A Practical Approach. Chichester, NY: John Wiley & Sons, 1995.
42. Hosmer DW, Jr, Lemeshow S. Applied Survival Analysis. Regression Modeling of Time to Event Data. New York: John Wiley & Sons, 1999.
43. Cleves M. Analysis of multiple failure-time data with Stata. Stata Technical Bulletin. 1999;
44. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer, 2000.
45. Callender GR. Malignant melanocytic tumors of the eye. A study of histologic types in 111 cases. Trans Am Acad Ophthalmol Otolaryngol. 1931;36:131-140.
46. McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol. 1982;13:123-132.
47. Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol. 1983;101:1894-1899.
48. Liu W, Dowling JP, Murray WK, McArthur GA. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol. 2006;142:1551-1558.
49. Paridaens AD, Seregard S, Minassian D, Hungerford JL, McCartney AC. AgNOR counts in conjunctival malignant melanoma lack prognostic value. Br J Ophthalmol. 1992;76:621-623.
50. Clark WH, Elder DE, Guerry DP. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;1893-1904.
51. Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-1310.
52. Crawford JB. Conjunctival melanomas: prognostic factors a review and an analysis of a series. Trans Am Ophthalmol Soc. 1980;78:467-502.
53. Piras F, Colombrari R, Minerba L, Murtas D, Floris C, Maxia C, Corbu A, Perra MT, Sirigu P. The predictive value of CD8, CD4, CD68 and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer. 2005;104:1248-1254.
54. de la Cruz POJ, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990;65:112-115.
55. Whelchel JC, Farah SE, McLean IW, Burnier MN. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci. 1993;34:2603-2606.
56. Chen X, Maniotis AJ, Majumdar D, Pe'er J, Folberg R. Uveal melanoma cell staining for CD34 and assessment of tumor vascularity. Invest Ophthalmol Vis Sci. 2002;43:2533-2539.
57. Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci. 2003;44:1008-1011.